Although NSCLC patients whose tumors bear the EGFR mutation or deletion often show better clinical outcomes to EGFR-TKIs treatments, a large proportions of these patients (50–60%) eventually develop acquired resistance to TKIs caused by a secondary mutation, such as the T790M mutation [73–75]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.